文献速递前列腺增生与排尿功能障碍

水蒸气热疗治疗良性前列腺增生相关下尿路症状的多中心随机假对照试验最终5年结果

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
PubMed 文献 · J Urol · 2021-04-19

该多中心随机假对照试验纳入197例50岁以上、IPSS≥13、最大尿流率≤15 ml/s、前列腺体积30-80 cc的良性前列腺增生患者,评估水蒸气热疗(Rezūm™)的5年疗效。治疗组下尿路症状在3个月内显著改善并持续至5年(IPSS降低48%,生活质量提高45%,最大尿流率改善44%,BPH影响指数下降48%),手术再治疗率4.4%,无器械或操作相关新发勃起功能障碍报告。交叉组5年结果相似。

要点

  • 水蒸气热疗后3个月内下尿路症状显著改善,疗效持续至5年。
  • 5年手术再治疗率为4.4%,未报告新发持续性勃起功能障碍。
  • 交叉组5年结果与治疗组相似,支持该疗法对梗阻性侧叶和中间叶的有效性。

核心结论

  • 水蒸气热疗可提供显著且持久的症状缓解和尿流率改善至5年,手术再治疗率低,不影响性功能。

研究设计与样本

  • 多中心随机假对照试验,纳入197例50岁以上、IPSS≥13、最大尿流率≤15 ml/s、前列腺体积30-80 cc的良性前列腺增生患者,随访5年;对照组61例中53例交叉后接受治疗并随访5年。

主要发现

  • 治疗组5年时IPSS降低48%,生活质量提高45%,最大尿流率改善44%,BPH影响指数下降48%。
  • 5年手术再治疗率为4.4%,未报告器械或操作相关新发持续性勃起功能障碍。
  • 交叉组5年结果与治疗组相似。

关键数值与推荐

  • 纳入标准:年龄>50岁,IPSS≥13,最大尿流率≤15 ml/second,前列腺体积30-80 cc。
  • 疗效指标:IPSS降低48%,生活质量提高45%,最大尿流率改善44%,BPH影响指数下降48%。
  • 手术再治疗率4.4%。

临床怎么用

  • 水蒸气热疗可作为中度至重度良性前列腺增生相关下尿路症状的微创治疗选择,尤其适用于希望保留性功能的患者。
  • 治疗时可根据前列腺尿道长度确定每叶的蒸气治疗次数,并酌情处理中叶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODS: A total of 197 subjects >50 years of age with International Prostate Symptom Score ≥13, maximum flow rate ≤15 ml/second and prostate volume 30 to 80 cc were randomized and followed for 5 years. From the control arm of 61 subjects, a subset of 53 subjects requalified and after 3 months received treatment as part of the crossover group and were also followed for 5 years. The total number of vapor treatments to each lobe of the prostate was determined by length of prostatic urethra and included middle lobe treatment per physician discretion. RESULTS: Significant improvement of lower urinary tract symptoms was observed at <3 months post-thermal therapy, remaining durable through 5 years in the treatment group (International Prostate Symptom Score reduced 48%, quality of life increased 45%, maximum flow rate improved 44%, Benign Prostatic Hyperplasia Impact Index decreased 48%). Surgical re-treatment rate was 4.4% with no reports of device or procedure related sexual dysfunction or sustained de novo erectile dysfunction. Results within the crossover group were similar through 5 years. CONCLUSIONS: Minimally invasive treatment with water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical re-treatment rates and without impacting sexual function. It is a versatile therapy, providing successful treatment to obstructive lateral and middle lobes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021. PMID: 33872051. doi:10.1097/JU.0000000000001778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。